baber/WOPTO huggingface dataset:
Patent NZ-563645-A (NZ)
Title: Use of NK cell inhibition to facilitate persistence of engrafted MHC-I negative cells
Inventor: BLAZAR BRUCE
IPC: A61K39/00
Filed: 2005-05-05
Abstract: A composition comprising (1) a means for inhibiting natural killer cell function, (2) non-ES, non EG, non-germ cells wherein the non-ES, non-EG, non-germ cells express one or more of telomerase, oct 3/4, rex-1, rox-1 or sox-2, and (3) a pharmaceutically acceptable carrier. Further disclosed is the use of the composition for the treatment of an adverse immune response caused by the non-ES, non EG, non-germ cells. The composition can be used to increase persistence and/or engraftment of MHC-I negative cells, such as multipotent adult progenitor cells (MAPCs).
Patent NZ-567222-A (NZ)
Title: Novel use of IL-1beta compounds
Inventor: LOWE PHIL
IPC: A61P37/00
Filed: 2006-10-24
Abstract: Provided is the se of an IL-1 beta binding antibody or a fragment thereof for manufacture of a medicament for the treatment of systemic onset juvenile idiopathic arthritis, the antibody comprising both heavy (VH) and light chain (VL) variable domains in which said IL-1beta binding antibody comprises at least one antigen binding site comprising: a) an immunoglobulin heavy chain variable domain (VH) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Val-Tyr-Gly-Met-Asn, said CDR2 having the amino acid sequence Ile-Ile-Trp- Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly, and said CDR3 having the amino acid sequence Asp-Leu-Arg-Thr-Gly-Pro; and b) an immunoglobulin light chain variable domain (VL) which comprises in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Ser-Ile-Gly-Ser-Ser-Leu-His, said CDR2' having the amino acid sequence Ala-Ser-Gln-Ser-Phe-Ser, and said CDR3' having the amino acid sequence His-Gln-Ser-Ser-Ser-Leu-Pro.
Patent NZ-567239-A (NZ)
Title: Meat based food product
Inventor: NIELSEN PER MUNK
IPC: A23L13/00
Filed: 2006-11-01
Abstract: Disclosed is a method for producing a meat based food product comprising a) contacting meat with a phospholipase A1 or phospholipase A2; b) heating the phospholipase treated meat; and c) producing a food product from the phospholipase treated meat; wherein step b) is conducted before, during or after step c).
Patent NZ-584078-A (NZ)
Title: A solid block acid containing cleaning composition which comprises a mineral acid, sulfamic acid, urea and a non-ionic surfactant
Inventor: SAUTER JOACHIM
IPC: C01B17/98
Filed: 2007-11-05
Abstract: Disclosed is a solid block acid containing cleaning composition including based on the composition a) 10 - 75 wt-% of at least one liquid mineral acid selected from the group consisting of phosphoric acid, sulphuric acid, sulphurous acid, and nitric acid; b) 5 - 60 wt-% of sulfamic acid; c) 15 - 80 wt-% of at least one carboxylic acid selected from the group consisting of citric acid monohydrate, hydroxyacetic acid, maleic acid, succinic acid, glutaric acid and adipinic acid; d) 5 - 40 wt-% urea; e) 0.1 - 10 wt-% of at least one non-ionic surfactant; and the rest up to 100 wt-% is water; wherein the composition contains less than 1 wt-% nonylphenol ethoxylates and halogen compounds.
Patent NZ-586161-A (NZ)
Title: Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
Inventor: MAUS JOACHIM
IPC: A61K31/4745
Filed: 2008-12-23
Abstract: Disclosed is the use of imiquimod, 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, for treating colorectal polyps/polyposis or early colorectal cancerous changes in a patient.
Patent NZ-586678-A (NZ)
Title: Aqueous herbicide formulation comprising an HPPD inhibitor, an encapsulated chloroacetamide/isoxazoline, glyphosate/glufosinate and a pH adjuster
Inventor: NELSON ALAN FREDERICK
IPC: A01N43/80
Filed: 2009-02-12
Abstract: Disclosed are herbicidal formulations comprising: (a) an aqueous phase; (b) a p-hydroxyphenylpyruvate dioxygenase inhibitor (HPPD inhibitor), such as the triketone HPPD inhibitors mesotrione or tembotrione, in suspension in the aqueous phase; (c) an encapsulated chloroacetamide selected from the group consisting of acetochlor, alachlor, dimethenamid, metolachlor and S-metolachlor; (d) glyphosate and/or glufosinate or an agrochemically acceptable salt thereof, in solution in the aqueous phase; and (e) toluene sulfonic acid in an amount to provide a pH from about 3 to about 7. Also disclosed is a process to control unwanted vegetation that involves applying the herbicide to the locus of the unwanted vegetation.
Patent NZ-588280-A (NZ)
Title: Compositions and methods for inhibiting expression of eg5 and vegf genes
Inventor: BUMCROT DAVID
IPC: C12N15/113
Filed: 2009-03-05
Abstract: Disclosed is a composition comprising a first double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human kinesin family member 11 (Eg5/KSP) gene in a cell and a second dsRNA for inhibiting expression of a human VEGF in a cell, wherein: both said first and said second dsRNA are formulated in a stable nucleic acid lipid particle (SNALP) comprising 1,2,-dilinoleyloxy-N,N-dimethyl-3-aminopropane (DLinDMA), cholesterol, dipalmitoyl phosphatidylcholine (DPPC), and (3-N-[ù-Methoxy poly(ethylene glycol)2000)carbamoyl]-1,2-dimyristyloxy-propylamine) (PEG2000-C-DMA); said first dsRNA consists of a first sense strand and a first antisense strand, and said first sense strand comprises a first sequence and said first antisense strand comprises a second sequence complementary to at least 15 contiguous nucleotides of SEQ ID NO:1311 (5'- UCGAGAAUCUAAACUAACU-3'), wherein said first sequence is complementary to said second sequence and wherein said first dsRNA is between 15 and 30 base pairs in length; and said second dsRNA consists of a second sense strand and a second antisense strand, said second sense strand comprising a third sequence and said second antisense strand comprising a fourth sequence complementary to at least 15 contiguous nucleotides of SEQ ID NO:1538 (5'- GCACAUAGGAGAGAUGAGCUU-3'), wherein said third sequence is complementary to said fourth sequence and wherein each strand is between 15 and 30 base pairs in length.
Patent NZ-593653-A (NZ)
Title: Treatment of inflammatory bowel diseases with mammal beta defensins
Inventor: KJAER TANJA MARIA ROSENKILDE
IPC: A61K38/17
Filed: 2009-07-17
Abstract: Disclosed is the use of Human beta Defensin 2 in the manufacture of a medicament adapted for oral administration in the treatment of inflammatory bowel disease.
Patent NZ-597583-A (NZ)
Title: Treatment of alzheimer’s disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
Inventor: LABRIE FERNAND
IPC: A61P15/12
Filed: 2010-06-16
Abstract: Disclosed is the use of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3Beta,17Beta-diol, and 4-androstene-3,17-dione in the preparation of a medicament for preventing, reducing or eliminating the incidence of at least one symptom due to the menopause selected from the group consisting of Alzheimer’s disease, loss of cognition, memory loss, and dementia, as part of a combination therapy with a therapeutically effective amount of a selective estrogen receptor modulator or an antiestrogen, wherein the selective estrogen receptor modulator or antiestrogen is used to decrease the risk of breast, uterine and endometrial cancer normally present in postmenopausal women and to prevent bone loss, osteoporosis, hypertension, insulin resistance, diabetes, obesity and atherosclerosis.
Patent NZ-597651-A (NZ)
Title: Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
Inventor: NIMMERJAHN FALK
IPC: A61K39/395
Filed: 2007-07-03
Abstract: Disclosed is a pharmaceutical formulation comprising a purified or a modified polypeptide preparation containing at least one IgG Fc region in combination with a suitable carrier or diluent, the purified or modified polypeptide preparation having a higher content of at least one galactose moiety connected to a respective terminal sialic acid moiety by a alpha 2,6 linkage than an unpurified or unmodified preparation of the Fc containing polypeptide, and wherein said purified or modified preparation has a higher anti-inflammatory activity and lower cytotoxic activity as compared to the unpurified or unmodified preparation as a result of said higher content of glycosylated Fc regions.
Patent NZ-600082-A (NZ)
Title: Stem cell aggregate suspension compositions and methods for differentiation thereof
Inventor: GREEN CHAD
IPC: C12N5/00
Filed: 2012-05-18
Abstract: Disclosed is a bioreactor comprising primate pluripotent stem cell-derived cell aggregates in suspension, wherein the primate pluripotent stem cell-derived cell aggregates in suspension are generated by a method comprising: a. providing a culture of undifferentiated adherent primate pluripotent 5 stem cells; b. disassociating the adherent primate pluripotent stem cell culture of step (a) into a primate pluripotent stem single cell suspension; c. seeding the primate pluripotent stem cell single cell suspension in a defined culture medium that supports undifferentiated growth of the primate pluripotent stem cells, thereby forming a primate pluripotent stem cell single cell suspension culture; d. agitating the primate pluripotent stem single cell suspension culture at low shear, wherein the primate pluripotent stem single cells in the suspension form substantially uniform primate pluripotent stem cell aggregates; and e. contacting the primate pluripotent stem cell aggregates in suspension with a differentiating culture condition wherein primate pluripotent stem cell aggregates in suspension from primate pluripotent stem derived cell aggregates in suspension, thereby generating primate pluripotent stem derived cell aggregates in suspension.
Patent NZ-601986-A (NZ)
Title: Power conversion system and method
Inventor: DATTA RAJIB
IPC: H02M5/00
Filed: 2012-08-22
Abstract: Disclosed is a power conversion system which includes a power transformer (62) for receiving AC power at a first voltage from an input side (52) and for delivering AC power at a second voltage to an output side (56). A power converter (60) is also included in the power conversion system wherein the power converter (60) includes an input side converter on the input side (52) and an output side converter on the output side (56) coupled through a plurality of DC links. A converter controller in the power converter (60) provides control signals to the input side converter and the output side converter for regulating an active power and a reactive power flow through the power converter (60). Each of the input side converters and the output side converters includes at least two power converter transformers coupled between respective power converter bridges coupled to the plurality of DC links and the input side (52) or to the plurality of DC links and the output side (56).
Patent NZ-602362-A (NZ)
Title: Imidazopyridines syk inhibitors
Inventor: KROPF JEFFREY E
IPC: A61P11/00
Filed: 2011-03-11
Abstract: Disclosed are imidazopyridines compounds of formula (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. Examples of compounds of formula (I) are: N-(3,4-dimethoxyphenyl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine, N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5,6-dimethoxypyridin-2-amine and N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]pyrimidin-4-amine.
Patent NZ-606950-A (NZ)
Title: Compounds for the reduction of beta-amyloid production
Inventor: BOY KENNETH M
IPC: A61K31/395
Filed: 2011-07-12
Abstract: Disclosed are 7-(heteroaryl)-18-phenyl-10,13,14,16,17,18-hexahydro-15,2-(azeno)-8,4-(metheno)cyclopenta[h][1,6,10,12]oxatriazacycloheptadecine derivatives as represented by the general formula (I), including pharmaceutically acceptable salts thereof, wherein R1 is a nitrile group, or is a five- or six-membered optionally substituted heteroaromatic ring; A is selected from O, CH2, or is a bond; B is selected from -(CH2)n-, -CH=CH-, and -(CH2)nCH(R3)-; D is selected from O, NR3, -CH(OH)-, -CH(OR3)-, and -CH(N[R3]2)-, or is a bond; E is selected from -(CH2)n-, -CH=CH- and -(CH2)nCH(R3)-; F is selected from O and NR3, or is a bond; G is selected from –CH2–, –CH2–CH2–, NR3, and –N(R3)–CH2-; S, T, and U are independently selected from carbon and nitrogen, with the proviso that no more than one of S, T, and U is nitrogen; R2 is optionally one, two, or three of the following: halogen, alkoxy, OCF3, alkyl, CN; R3 is independently alkyl or hydrogen; and n is 0-3. Representative compounds include (11E)-7-(4-chloro-1H-imidazol-1-yl)-18-phenyl -10,13,14,16,17,18-hexahydro-15,2-(azeno)-8,4-(metheno)cyclopenta[h][1,6,10,12]oxatriazacycloheptadecine, 7-(4-chloro-1H-imidazol-1-yl)-17-phenyl-11,12,13,15,16,17-hexahydro-10H-14,2-(azeno)-8,4-(metheno)cyclopenta[g][1,5,9,11]oxatriazacyclohexadecine, 7-cyano-19-(4-fluorophenyl)-12-methyl-11,12,13,14,15,17,18,19-octahydro-10H-16,2-(azeno)-8,4-(metheno)cyclopenta[i][1,4,7,11,13]oxatetraazacyclooctadecine, (11Z)-7-(3-methyl-1H-1,2,4-triazol-1-yl)-18-phenyl-10,13,14,16,17,18-hexahydro-15,2-(azeno)-8,4-(metheno)cyclopenta[h][1,6,10,12]oxatriazacycloheptadecine, (11Z)-18-(4-fluorophenyl)-7-(3-methyl-1H-1,2,4-triazol-1-yl)-10,13,14,16,17,18-hexahydro-15,2-(azeno)-8,4-(metheno)cyclopenta[h][1,6,10,12]oxatriazacycloheptadecine, (11Z)-18-(2,4-difluorophenyl)-7-(5-methyl-1H-1,2,4-triazol-1-yl)-10,13,14,16,17,18-hexahydro-15,2-(azeno)-8,4-(metheno)cyclopenta[h][1,6,10,12]oxatriazacycloheptadecine, (11E)-7-(3-methyl-1H-1,2,4-triazol-1-yl)-18-phenyl-10,13,14,16,17,18-hexahydro-15,2-(azeno)-8,4-(metheno)cyclopenta[h][1,10,12]oxadiazacycloheptadecine and 19-(4-fluorophenyl)-17-methyl-7-(3-methyl-1H-1,2,4-triazol-1-yl)-11,12,13,14,16,17,18,19-octahydro-10H-15,2-(azeno)-8,4-(metheno)pyrido[3,4-h][1,6,10,12]oxatriazacycloheptadecine. Further disclosed is a pharmaceutical composition for the treatment of disorders responsive to the reduction of ß-amyloid peptide production comprising a therapeutically effective amount of a compound as defined above in association with a pharmaceutically acceptable carrier or diluent, and particularly for the treatment of Alzheimer’s Disease (AD), Down Syndrome, mild cognitive impairment (MCI), cerebral amyloid angiopathy (CAA), dementia with Lewy bodies (DLB), amyotrophic lateral sclerosis (ALS-D), inclusion body myositis (IBM), age-related macular degeneration, and cancer.
Patent NZ-607682-A (NZ)
Title: A garment for supporting a wearer’s breasts
Inventor: GIBBARD KYLIE MARGARET
IPC: A41D7/00
Filed: 2010-08-02
Abstract: 607682 A garment (1) for supporting a wearer’s breasts has a band (3) for encircling a wearer’s torso and a pair of cups (5) for receiving at least a major part of a wearer’s breast, and a pair of shoulder straps (9), each shoulder strap extending from a corresponding cup to a back portion of the garment. The garment has a pair of panel portions (7), each panel portion extending between the band and a corresponding cup of the pair of cups. Each panel portion has a folding portion that is foldable relative to the pair of cups (5) so that the folding portions lie between a wearer’s breasts and a wearer’s torso, in use. The band (3), the shoulder straps (9) and the panel portions (7) are arranged such that the weight of a wearer’s breasts are supported by both the shoulder straps and the band.
Patent NZ-609792-A (NZ)
Title: Non-fat dry milk production processes for cheesemaking
Inventor: MERRILL RICHARD K
IPC: A23C19/00
Filed: 2008-10-03
Abstract: Disclosed is a dairy composition comprising enzyme hydrolysed milk proteins, a buffer compound, and a sequestrant for calcium, wherein there is substantially no aggregation of the enzyme hydrolysed milk proteins, and wherein the sequestrant is added in an amount sufficient to prevent the enzyme hydrolysed proteins from coagulating. Also disclosed is a method of making a powdered dairy composition, the method comprising: adding a buffer compound to a milk composition, wherein the buffer compound gives the milk composition a pH of 5.5 or more; adding a sequestrant for calcium to the milk composition; adding a milk coagulating enzyme to the milk composition to form a treated milk; and forming the treated milk into the powdered dairy composition, wherein a concentration of free calcium ions in the treated milk is controlled by the sequestrant for calcium, and wherein the powdered dairy composition comprises substantially no aggregation of enzyme hydrolysed milk proteins due to the sequestrant’s reduction of calcium ion concentration in the treated milk.
Patent NZ-614184-A (NZ)
Title: Baclofen and acamprosate based therapy of neurogical disorders
Inventor: COHEN DANIEL
IPC: A61P25/28
Filed: 2012-03-01
Abstract: Provided are compositions comprising a combination of baclofen and acamprosate and their use in the treatment of neurological disorders. Further provided are compositions comprising the combination with one or more additional active ingredients selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, aminocaproic acid, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplerenone, fenoldopam, leflunomide, levosimendan, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, bromocriptine or torasemide. The neurological disorders for treatment with the compositions include Alzheimer’s disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), neuropathies, alcoholism or alcohol withdrawal, Huntington’s disease (HD) and spinal cord injury.
Patent NZ-618227-A (NZ)
Title: Titanium dioxide photocatalytic compositions and uses thereof
Inventor: AVERETT STEWART BENSON
IPC: B01J21/06
Filed: 2012-05-03
Abstract: Disclosed are photocatalytic compositions comprising zinc (Zn) doped titanium dioxide (TiO2) nanoparticles, wherein the ratio of titanium dioxide nanoparticles to zinc is from about 5 to about 150. Also disclosed are photocatalytic compositions where the titanium dioxide is further doped with silicon dixoide (SiO2). Further provided are methods for treating or preventing microbial diseases and infestations in plants and methods for increasing crop yield of a plant by applying the photocatalytic compositions taught herein to the surface of a plant. A method for treating microbial diseases on a surface applies the photocatalytic compositions taught herein to a surface illuminated by artificial light.
Patent NZ-618458-A (NZ)
Title: Methods and systems for matching records and normalizing names
Inventor: Zhang ling qin
IPC: G06F17/30
Filed: 2010-01-14
Abstract: Disclosed is a computer-implemented method of matching records. The method is performed by extracting a key record including key fields from a first data source; and retrieving a candidate record including candidate fields from a second data source. The candidate fields correspond to the key fields. A numerical record including numerical fields is then computed, by a processor, by comparing the key fields and the candidate fields using comparison functions. The numerical fields are result values of the comparison functions. The method further includes applying matching functions to the numerical fields. The matching functions are determined by an additive logistic regression method. A determination is then made of whether the key record and the candidate record are a match based on a sum of results of the matching functions.
Patent NZ-621633-A (NZ)
Title: Bacterial adherence and anti-adherence to mucus, epithelial cells and other cells
Inventor: DAWSON KARL A
IPC: G01N33/00
Filed: 2010-07-08
Abstract: Disclosed is a kit for the non-radioactive analysis of adherence and anti-adherence between bacteria and mucus comprising: a) a solid support having mucus coated thereon, wherein the mucus coated support is prepared via scraping mucus from an intestinal surface, suspending the mucus in a buffer and immobilizing the mucus on the solid support; b) bacteria; c) a primary antibody specific for the bacteria; d) a non-radioactive, detectably labeled secondary antibody specific for the primary antibody bound to bacteria; e) a non-radioactive substrate that allows the visualization of the detectably labeled secondary antibody; and f) an agent that modulates bacterial adherence to mucus.
Patent NZ-625544-A (NZ)
Title: System for indicating movement of an article from one position or orientation to another position or orientation
Inventor: ECKERMANN BRONTE
IPC: A63B71/06
Filed: 2010-10-18
Abstract: A cricket stump and bail assembly including at least one stump, at least one bail (1, 2) and at least one indicator (34, 35) responsive to a trigger event which indicates to an observer that displacement of either the bail (1, 2) or the stump has occurred from a first position to a second position. Assembly also includes an electronic circuit (3) retained inside either the bail (1, 2) or the stump. The circuit (3) incorporates the indicator (34, 35) and includes a power source (54) capable of activating the indicator (34, 35). A sensor is capable of detecting the displacement in response to the trigger event and enables the power source (54) to activate the indicator (34, 35). The indicator is at least one LED.
Patent NZ-627807-A (NZ)
Title: Blade for a reciprocating saw and handsaw
Inventor: KRISTIAN AUS
IPC: B23D61/12
Filed: 2014-07-23
Abstract: A blade 10 suitable for a handheld reciprocating saw 12, comprises a number of forward facing blades 16 configured to cut in a first direction of movement A, and a number of backward facing blades 18 configured to cut in a second direction B. The teeth are arranged along the cutting edge of the blade 10 in alternating groups of like teeth. The length of the blade 10 is greater than its height.
Patent NZ-629108-A (NZ)
Title: Method of making a 3d object from composite material
Inventor: TRONDL WILLIAM ANTON
IPC: B32B7/02
Filed: 2013-03-14
Abstract: Disclosed is a method of producing an object made of a composite material. The method includes bonding a series of shaped sections of material each with a laminated face to form the object. The surface of the object is laminated with composite material so that when laminated, the internal and external laminations are tied together to form an array of structural members, thereby forming the composite object without using a mould.
Patent NZ-700849-A (NZ)
Title: Mobile garbage bin
Inventor: CIAMPICHETT EMANUELE
IPC: B65F1/14
Filed: 2011-03-22
Abstract: A mobile garbage bin 1 comprising a side wall and a base which together define an interior cavity 6, the wall comprising a plurality of stiffening formations 26 that extend along the side wall from the base, and one or more panels 4a, 4b located between the stiffening formations 26, the stiffening formations 26 and the one or more panels 4a, 4b being structured such that the or each panel 4a, 4b has greater flexibility than the stiffening formations 26 wherein the side wall is generally polygonal in cross section perpendicular to the longitudinal direction and the stiffening formations 26 extends along mutually inclined faces of the side wall, and the stiffening formations 26 and the panels 4a, 4b are integrally formed such that the stiffening formations 26 have a greater material thickness than the panels 4a, 4b.